Moving beyond breast cancer, recently published data demonstrate that targeting CAIX/CAXII is a promising therapeutic avenue in glioblastoma multiforme (GBM), when used in combination with standard of care chemotherapy. This evidence concerns the gene CA9 and breast carcinoma.